文献速递乳腺癌

液体活检免疫抑制特征预测三阴性乳腺癌新辅助化疗反应

Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.
PubMed 文献 · Eur J Cancer · 2020-09-29

该研究在诊断时对三阴性乳腺癌患者联合代谢组学、外泌体循环miRNA和流式细胞术,结合肿瘤免疫组化构建新辅助化疗反应预测模型。血液来源的色氨酸代谢物和早期髓源性抑制细胞水平可显著预测新辅助化疗反应,IDO1表达与循环色氨酸及eMDSC水平相关。循环外泌体miRNA亦可在化疗前预测不良反应。

要点

  • 血液色氨酸代谢物与eMDSC水平可预测三阴性乳腺癌新辅助化疗反应。
  • 肿瘤IDO1表达与循环色氨酸负相关、与eMDSC水平正相关。
  • 循环外泌体miRNA可在化疗前预测不良新辅助化疗反应。

核心结论

  • 免疫系统抑制通路在调节三阴性乳腺癌新辅助化疗反应中起关键作用。
  • 肿瘤细胞与eMDSC之间的交互机制加剧免疫抑制,有望用于识别不良新辅助化疗反应者。

研究设计与样本

  • 在诊断时对三阴性乳腺癌患者联合代谢组学、外泌体循环miRNA和流式细胞术,并结合穿刺活检肿瘤免疫组化构建预测模型。
  • 共培养患者来源的早期髓源性抑制细胞与三阴性乳腺癌细胞系并研究其交互作用。

主要发现

  • 血液来源的色氨酸代谢物和eMDSC水平构成的新型免疫抑制特征可显著预测新辅助化疗反应。
  • 肿瘤细胞IDO1表达与循环色氨酸水平呈负相关,与eMDSC水平呈正相关。
  • 一组靶向免疫成熟通路的循环外泌体miRNA可在化疗前预测不良新辅助化疗反应。
  • 三阴性乳腺癌细胞系与患者来源eMDSC共培养后IDO1表达增加,并促进eMDSC增殖。

临床怎么用

  • 液体活检免疫抑制特征有望在治疗早期识别新辅助化疗不良反应者,以考虑替代策略如早期手术切除。
  • 对识别出的不良反应者,可探索替代免疫治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Triple-negative breast cancer (TNBC) is characterised by high pathological complete response to neoadjuvant chemotherapy (NAC). However, refractory and poor NAC responders still face very poor outcome, emphasising the urgent need for tools that facilitate identification of these patients, so that surgery or alternatives to NAC are considered early in the treatment protocol. MATERIALS AND METHODS: We combined metabolomics, exosome circulating miRNAs and flow cytometry experimental approaches in TNBC patients at diagnosis with immunohistochemistry in needle biopsy tumours to generate NAC-response predictive models. We also co-cultured and studied crosstalk between isolated patient-derived early myeloid-derived suppressor cells (eMDSCs) and TNBC cancer cell lines. RESULTS: Blood-derived liquid biopsy biomarkers display a novel immunosuppressive profile of tryptophan-derived metabolites and eMDSC levels that significantly predict NAC response. Notably, indoleamine 2,3-dioxygenase 1 (IDO1) expression in tumour cells inversely correlated with circulating tryptophan levels but directly correlated with the level of eMDSCs. In addition, a set of circulating exosome miRNAs that target pathways of immune maturation also predicted poor NAC response prior to chemotherapy. Interestingly, expression of IDO1 increased when TNBC cell lines were co-cultured with patient-derived eMDSCs and this, in turn, promoted proliferation of eMDSCs. CONCLUSION: Our findings demonstrate that the suppressive pathways of the immune system play a key role in modulating the NAC response in TNBC. We identify a crosstalk mechanism between tumour cells and eMDSCs that exacerbates immunosuppression. These results provide a potential new tool to identify poor NAC responders for alternative strategies of treatment, including early surgical resection of the tumour, and to explore in them alternative immune therapies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Salvador-Coloma C, Santaballa A, Sanmartín E, et al. Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Cancer. 2020. PMID: 32987253. doi:10.1016/j.ejca.2020.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。